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Perhaps our undying fascination with any topic related
to sex arises from our desire to understand all features
shared between man and woman and, more important,
to discover those features which distinguish us from one
another. During the past decade, scientists have begun
to unlock differences between the sexes through molec-
ular and genetic dissection of mammalian sexual differ-
entiation. This area of research exemplifies a successful
amalgamation of human, mouse, and molecular studies
that are beginning to create a general understanding of
this developmental event. Here, we have chosen not to
cover the detailed embryology of gonadal and sexual
differentiation (recently reviewed by Swain and Lovell-
Badge 1999); we focus instead on concepts emerging
from the numerous in vitro, in vivo, and genetic analyses.
In vitro analyses have now outlined the molecular basis
of testis development, although the function SRY/Sry,
which apparently initiates this process, is still a complete
mystery. Genetic analyses now suggest that, whereas
gene dosage appears to be important in human sexual
development, this effect is far less crucial in laboratory-
mouse strains. On the other hand, reverse genetic ex-
periments in these same mouse-model systems have led
both to discovery and to elimination of candidate genes
proposed to direct this developmental process. Finally,
recent findings have served also to underscore the dif-
ferences and similarities shared betweenmammalian and
invertebrate sexual differentiation.
Gonadal and Sexual Development
Regardless of genetic sex, embryos undergo an indif-
ferent stage of sexual development, marked by the ap-
pearance of bipotential gonads and internal and external
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genitalia that are sexually indeterminate. Both male and
female embryos initially develop with primitive male and
female reproductive tracts. The Mu¨llerian duct gives rise
to oviducts, uterus, and upper vagina, and the Wolffian
duct is the precursor of the epididymis, vas deferens,
seminal vesicle, and ejaculatory duct. In males, sexual
determination culminates in the secretion of testicular
hormones, which cause male-specific development of the
bipotential reproductive system; this process is referred
to as “primary sexual differentiation.” In the absence of
gonads, embryos develop female reproductive tracts and
genitalia, so female differentiation is considered a default
pathway. Sex reversal in males can result from the ab-
sence of testicular hormones or from the failure of those
hormones to signal in target tissues. Conversely, if female
embryos are exposed to testicular hormones, they can
undergo aspects of male sexual differentiation, despite
the absence of testes.
Our understanding of male sexual development is
much more extensive than our knowledge female de-
velopment, largely because three essential testicular hor-
mones have been identified. Several decades ago, two of
these male-differentiation hormones were discovered
when Jost performed the now-classic experiment of
transplantation of fetal rabbit testes into female hosts.
Sertoli cells secrete a TGF-b superfamily hormone called
“Mu¨llerian inhibiting substance” (MIS, also known as
“anti-Mu¨llerian hormone” [AMH]), which causes the
Mu¨llerian duct to regress (reviewed in Behringer 1995).
Leydig cells secrete testosterone, which maintains the
Wolffian duct; also, testosterone is metabolized into
other steroids, which masculinize the external genitalia
and specific brain regions. More recently, a third hor-
mone has been identified by reverse genetics in mice.
The Leydig-cell hormone, insulin-like hormone 3
(InsL3), is required for testicular descent (Zimmermann
et al. 1999). Consistent with their role in testis devel-
opment, MIS, InsL3, or steroidogenic enzymes produc-
ing testosterone are not present in the fetal ovary. More-
over, now it appears that synthesis of testosterone is
actively repressed in the embryonic stages of female de-
velopment (Vainio et al. 1999). Consequently, female
differentiation occurs because (i) without MIS, Mu¨ller-
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Figure 1 Sex-specific and shared regulatory factors involved in
male and female gonadal differentiation. Relative levels of expression
in the testis and ovary are indicated, by color codes, for each factor.
In mice, Sry expression commences at ∼10.5 dpc (Hacker et al. 1995;
Jeske et al. 1995).
ian ducts are maintained; (ii) without testosterone,Wolf-
fian ducts degenerate and female external genitalia de-
velop; and (iii) without InsL3, gonads remain in the
abdomen.
Regulatory Molecules in Mammalian Sex
Differentiation
Although the hormonal basis of sexual differentiation
is well understood, the molecular events initiated by
these testicular hormones remain unclear. Much more is
known about how expression of these testicular hor-
mones becomes restricted to males. Identification of sex-
determining genes either by human genetics or through
promoter analyses of genes encoding male hormones has
taught us three important facts. First, factors used to
establish the early indifferent gonad regulate these tes-
ticular hormones and act at multiple stages in the em-
bryonic and adult gonad. Second, these factors are nei-
ther sex specific nor gonad specific. Thus, whereas the
expression of target genes, including those required for
the synthesis of male hormones, is restricted to the em-
bryonic testis, the regulators of these hormones are not.
Finally, a straightforward cascade of gene activation and/
or repression, as found in invertebrate systems, appears
not to be used in mammalian sexual development.
Rather, it seems that an intricate web of factors activates
downstream targets and that each factor is itself regu-
lated by a subset of these same genes.
Expression profiles of known sex-determining genes
have been described, and the general temporal and sex-
specific patterns, relative to each other, are shown in
figure 1. Currently, three genes have been implicated in
gonadal development—the orphan nuclear receptor Ste-
roidogenic factor-1 (SF-1, or Ftz-F1), the zinc-finger fac-
tor, Wilms tumor 1 (WT1), and the homeobox gene,
Lim-1. The only known sex-specific gene to be involved
directly in testis development is the Y-linked gene, SRY,
whose expression follows that of SF-1, WT1, and Lim-
1. The autosomal genes—Sox9, SF-1, and DMRT1—all
exhibit a sexually dimorphic expression pattern after
commencement of testis determination, although SF-1
expression resurfaces in the postnatal ovary. DMRT1 is
related to both mab-3 of Caenorhabditis elegans and
doublesex of Drosophila and, thus far, represents the
only structurally related gene known to participate in
sexual differentiation in both vertebrates and inverte-
brates (Raymond et al. 1999). Wnt4 is implicated in
ovarian development because of its role in the repression
of steroidogenesis. Other genes implicated in the mam-
malian sex-determination pathway are desert hedgehog
(Dhh), GATA-4, and DAX-1 (also known as “AHC”).
However, as discussed below, studies of human and
mouse mutants have formally ruled out roles for either
DAX-1 or Dhh in gonadal development (table 1).
Dosage of Regulatory Factors
Gene dosage of regulatory factors appears to be crit-
ical in normal human sex determination, as indicated in
table 1. This strategy for fine-tuning this developmental
process has only been revealed by analyzing the genotype
of human sex-reversed individuals, since dosage effects
do not appear to operate in genetically engineered
mouse-model systems. Heterozygous inbred Wt1 or SF-
1 (ftz-f1) mouse mutants exhibit normal gonadal de-
velopment, whereas human XY mutant heterozygotes
may be fully sex reversed or may present with milder
gonadal dysgenesis. Whether the phenotypic difference
between heterozygote humans and mice represents a fine
distinction in anatomy and physiology or whether it re-
flects the broad diversity of the human population versus
an inbred strain bred with selective pressures for high
fecundity is not clear. Given the conservation of factors
shared between mice and men in sexual development,
discussed below, the latter hypothesis seems more likely.
SRY
To date, the uniquely mammalian gene SRY, remains
the only sex chromosome–specific gene that actively par-
ticipates in gonadal development. Unsolved problems
abound regarding the function of SRY. SRY/Srywas pos-
itionally cloned on the short arm of the Y chromosome
(Koopman et al. 1990), and its candidacy as the testis-
determining factor (TDF) was confirmed when a 14-kb
Table 1
Dosage Effects and Phenotypes Observed in Human and Mouse Mutants of Sex-Linked and Autosomal Genes Involved in Mammalian Sex Determination
KARYOTYPE
AND GENOTYPE
EFFECTIVE GENE DOSAGE
PHENOTYPIC
SEX
OTHER PHENOTYPES
SRY SOX9 WT1 SF1 DMRT DAX1 Human Mouse
46,XX:
Wild type 0 2 2 2 2 2 Female
46,XY:
Wild type 1 2 2 2 2 1 Male
SRY 0 2 2 2 2 1 Female Testicular dysgenesis Not determined
SOX9/ 1 1 2 2 2 1 Female Campomelic dysplasia in XX and XY
heterozygote
Not determined
WT1/ 1 2 1 2 2 1 Female Renal nephropathy, Wilms tumor in XX and XY
heterozygote
Gonadal and kidney agenesis with defects in
heart, lung in homozygote
SF1/ 1 2 2 1 2 1 Female Adrenal
Insufficiency in heterozygote
Gonadal, adrenal, gonadotropic, and ventro-
medial-hypothalamus agenesis in
homozygote
DMRT/a 1 2 2 2 1a 1 Female Not determined Not determined
Duplication of Xp21(DAX1) 1 2 2 2 2 2 Female Not applicable Not applicable
DAX1 1 2 2 2 2 0 Male Adrenal insufficiency, normal testes, sporadic hy-
pogonadism/hypogonadotropism
Adrenal insufficiency, impaired
spermatogenesis
46,XX:
DAX1/ 1 2 2 2 2 0 Female Adrenal insufficiency, normal ovaries Adrenal insufficiency, normal ovaries
a Large deletion spanning both DMRT1 and DMRT2 (Raymond et al. 1999).
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mouse genomic-fragment transgene harboring Sry in-
duced male sexual development in a proportion of XX
mice (Koopman et al. 1991). In addition, data compiled
from several labs revealed that 20% of XY females
with pure gonadal dysgenesis (complete female pheno-
type and streak gonads) carry missense or nonsense mu-
tations clustered in the DNA-binding high-mobility
group (HMG) domain of the intronless SRY gene.Oddly,
as reviewed by Cameron and Sinclair (1997), 46,XY
males with these HMGmissense mutations may develop
normally, indicating that the penetrance of these mu-
tations is incomplete. Moreover, as shown in table 1,
the presence of XY females who carry an intact SRY
gene predicts that the developmental switch between
male and female is under multiple levels of genetic
control.
SRY has been known for its pivotal role as the sex-
determining gene for almost 10 years, but how SRY in-
itiates male gonadal differentiation at the molecular level
is still not clear. Because it possesses a 79-amino-acid
DNA-binding HMG domain, SRY is presumed to func-
tion as a DNA-binding protein to modify gene expres-
sion. As with other HMG-transcription factors, SRY
binds preferentially to a conserved DNA sequence and
causes DNA bending (Grosschedl et al. 1994). Despite
extensive in vitro studies to define the mechanics and
optimal DNA binding sites, bona fide downstream tar-
gets of SRY remain unidentified. By analogy to other
HMG factors, it seems likely that SRY may function as
a structural-bridging factor that nucleates the assembly
of the transcriptional machinery. To date, potential SRY
targets include those genes which are up-regulated dur-
ing early testicular development, such as Sox9, SF-1, SF-
1, DMRT1, GATA-4, Dhh, and the matrix metallopro-
teinase, Testatin (To¨ho¨nen et al. 1998). The other
structural motifs in the SRY protein are not understood,
and no functional interacting SRY protein partners have
yet been reported.
The question of how SRY functions is further com-
plicated by the striking sequence divergence observed
among different mammalian SRY species (Gubbay et al.
1990; Sinclair et al. 1990). Both the overall topology
and the protein sequence (outside the HMG motif) of
SRY differ greatly among species. Why would a protein
performing an important and conserved developmental
program evolve so quickly? The largest sequence vari-
ations can be found at either the amino- or carboxyl-
terminus of SRY, where the presence and/or number of
glutamine (CAG) repeats differs significantly between
mouse and rat and among different mouse species
(Tucker and Lundrigan 1993; J. Shen and H. A. In-
grham, unpublished data). Further in vitro and in vivo
analyses are needed to assess the potential roles of these
non-HMG regions in the sex-differentiation pathways.
In the absence of bona fide target genes, in vivo mapping
or new innovative molecular strategies will be critical
for a full dissection of the structure-function relationship
of Sry.
The attempt to detect SRY transcripts and protein in
mammals has met with limited success. To date, neither
immunohistochemical nor western-blot analyses have
confirmed the presence of Sry protein in embryonic go-
nadal tissue. Nonetheless, sensitive RNA-expression
studies reveal Sry transcripts in the gonadal portion of
the urogenital ridge, beginning at 10.5 days postcoitum
(dpc), peaking at 11.0 dpc, and then declining (Hacker
et al. 1995; Jeske et al. 1995; C. Nagamine, personal
communication). The basis for this transient peak of Sry
expression suggests that Sry triggers Sertoli-cell differ-
entiation but that it is dispensable in the maintenance
of testicular development. Promoter analyses of SRY/Sry
in cultured cell lines have defined a proximal promot-
er region for expression in cultured cell lines (Descloz-
eaux et al. 1998). Indeed, several conserved binding
sites—including those for SP-1, AP-1, and Oct-1—are
found in multiple species, but none has been shown to
be critical for Sry expression (Margarit et al. 1998).
Y chromosomes from Mus domesticus poschiavinus
(Ypos) or Mus musculus domesticus (Ydom) have been in-
troduced into the C57 Bl/6 genetic background, in order
to study the function of Sry in mice. Both Ypos and Ydom
chromosomes appear to carry a weakened allele of Sry,
and, in this genetic context, they are associated with a
variable rate of phenotypic female development in XY
animals. Although this phenomenon remains unexplai-
ned at the molecular level, linkage analyses indicate that
three autosomal loci (tda1, tda2, and tda3) modulate
Sry action, to cause sex reversal (Eicher et al. 1996). Sex
reversal can be variable in these Ydom mice, and the de-
gree of sex reversal has shown to be associated with the
duration of C57BL/6 Srydom expression (Lee and Taketo
1994), suggesting that timing and the expression levels
of Srydom could account for this sex-reversal phenome-
non. However, intrinsic differences among Srydom alleles
and/or strain-specific protein interactions with different
Srydom alleles are also possible. If precise timing and ex-
pression levels of Sry are critical for normal male sexual
development, as suggested by these data, then finely
tuned regulatory mechanisms governing Sry’s temporal
and spatial expression must exist. The ability to sex-
convert an XX mouse with the Sry genomic fragment
predicts that no other Y-specific genes are required in
this transcriptional event.
The DAX-1 Paradox
DAX-1 (also known as “AHC”) was initially identi-
fied as being a factor underlying familial X-linked ad-
renal hypoplasia congenita, a condition that presents as
early-onset adrenal insufficiency (Muscatelli et al. 1994;
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Zanaria et al. 1994). Excitement following the discovery
of the DAX-1 gene arose in part because this X-linked
gene was proposed to be the long-awaited ovary-deter-
mining factor, because it resided in the X-chromosome
duplicated region associated with dosage-sensitive sex
reversal (DSS). DSS occurs in XY individuals who carry
a tandem duplication of a 160-kb region on the short
arm of the X chromosome (table 1; also see and Bardoni
et al. 1994). However, in Dax1/ mice, ovarian devel-
opment proceeds normally, with only a subtle defect ob-
served in the adult ovary of sporadic fused follicles (table
1; also see Yu et al. 1998). A rare homozygous DAX1-
mutant female patient has also been identified who ex-
hibits small but normal ovaries (table 1; also see Merke
et al. 1999). Collectively, these data exclude an overt
role for DAX1 in ovarian development, as originally
proposed elsewhere (Zanaria et al. 1994; Swain et al.
1996).
Sex reversal in 46,XY patients with a duplication of
DAX1 led to the obvious hypothesis that heightened
expression of the DAX1 protein, an unusual orphan nu-
clear receptor, antagonizes the male program. Thus far,
there is good molecular support for this dosage hypoth-
esis (discussed below), but it does not fully account for
data obtained in mouse transgenic studies. Indeed, trans-
genic XY mice carrying multiple copies of Dax1 are not
feminized, despite an excess of both Dax1 mRNA and
protein in the testes (Swain et al. 1998). However, an
antagonistic effect of Dax1 on male development was
unmasked in the Ypos x C57/Bl6 mouse strain, which, as
described above, carries a weakened Sry allele. More-
over, introduction of a Sry transgene into XX mice,
which normally initiates testis development, fails to do
so in strains that carry multiple copies of theDax1 trans-
gene, suggesting that Dax1 can antagonize this Sry-me-
diated sex conversion. Collectively, these data are pro-
vocative, but they leave one pondering the simple
hypothesis that two doses of DAX1 lead to DSS. The
fact that Dax1 overexpression fails to sex-reverse a nor-
mal XY mouse is intriguing and suggests that mecha-
nisms of sex-reversal in DSS patients may be more com-
plex that simple dosage effects. Specifically, the site of
the transgene integration might not recapitulate a tan-
dem duplication inDAX1, or surrounding chromosomal
information in this 160-kb region may also contribute
to the DSS phenotype. Finally, it is formally possible that
another gene in this region is responsible for DSS.
Modulation of SF-1 by DAX1
Impaired spermatogenesis in Dax1/ mice is consis-
tent with the testicular-expression pattern of Dax1
(Ikeda et al. 1996; Tamai et al. 1996; Nachtigal et al.
1998; Yu et al. 1998) but is difficult to reconcile with
the model suggesting that Dax1, as a single-copy gene,
acts strictly by antagonizing Sry. Instead, these data sup-
port the notion that Dax1 contributes to embryonic and
adult testis function in both Sertoli and Leydig cells.
Moreover, the shared phenotypes observed in SF-1 and
DAX1/Dax1 loss-of-function mutants would predict
that DAX1 either activates SF-1 target genes or interacts
directly with SF-1 as a positive cofactor. Contrary to this
hypothesis, however, assays in transfected cells show that
Dax1 represses SF-1–mediated transcription (Ito et al.
1997; Lalli et al. 1997; Crawford et al. 1998; Nachtigal
et al. 1998).
In vivo data generated from yeast and mammalian
two-hybrid assays, as well as from biochemical experi-
ments, show that both the N-terminus and the ligand-
binding domain (LBD) of DAX1 physically interact with
SF-1 (Crawford et al. 1998; Nachtigal et al. 1998; M.
Nachtigal and H. A. Ingraham, unpublished data). Hu-
man and mouse DAX1 share a series of conserved
LXXLL motifs at their N-termini, in addition to one
such motif in the LBD region, motifs that are known to
nucleate protein-protein interactions by nuclear recep-
tor–superfamily members. The outcome of a Dax1:SF-
1 protein partnership might depend on which LXXLL
motif interacts with a similar motif in the LBD of SF-1.
Additionally, because classic nuclear receptors require
ligand to relieve repression by corepressors such as
SMRT and N-CoR, the binding of a still unknown
DAX1 ligand may unlock the activation functions of
DAX1. Thus far, all DAX1 missense mutations that are
associated with DAX1 dysfunction occur in the putative
LBD region; thus the function of the N-terminal repeats
remains elusive (reviewed in Zhang et al. 1998).
Natural or Targeted Mutations in Regulators of Sexual
Development
Perhaps surprisingly, no mouse strain with a null allele
of Sry has been described, despite the striking sex-re-
versal and gonadal-dysgenesis phenotypes in people with
SRY mutations. For other autosomal genes that are im-
plicated in the sex-determination cascade, human and
mouse mutants exist, but they do not always phenocopy
one another; this is especially true in the heterozygous
state (table 1). For instance, the heterozygote 46,XY hu-
man mutants of SOX9, WT1, and SF-1 are all sex-re-
versed, whereas heterozygote mouse mutants of these
same genes appear to be normal. It will be of great in-
terest to see whether this trend continues for other genes,
such as DMRT1, that are implicated in the sex-deter-
mination pathway (Raymond et al. 1999). Presently, nei-
ther sex-reversed 46,XY humans carrying just one allele
of DMRT1 nor mice carrying a targeted disruption of
the Dmrt1 gene have been reported. Despite apparent
differences, in gene-dosage effects, between mice and hu-
mans, mutants of both species illustrate that these sex-
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determining factors are essential for other developmental
processes, which are unrelated to gonadal differentia-
tion; these are outlined briefly in table 1.
Within the past decade, genetic studies have identified
many of the key players in the mammalian sex-deter-
mination pathway. It is uncertain how many more genes
will be found in this developmental pathway. One of the
great challenges will be to determine the molecular and
biochemical nature of this pathway, in which genetic
variation leads to such complex and variable pheno-
types. We now turn to some the recent progress in this
area.
MIS: A Molecular Model of Sex-Specific Gene
Expression
MIS is one of the few male-specific genes known, and
it has served as a model of sex-specific gene expression.
Consequently, MIS transcription is the best-understood
aspect of sexual differentiation at a molecular level, and
it is regulated by many of the autosomal factors de-
scribed above. Promoter studies of the MIS gene reveal
a 180-bp region that is both necessary for reporter-gene
expression in Sertoli cells (Shen et al. 1994) and sufficient
to recapitulate the normal expression pattern of MIS in
transgenic mice (Giuili et al. 1997).
Regulation of MIS by SF-1/Sox9/WT1/GATA-4
A binding site for SF-1 within the 180-bp proximal
promoter is required for MIS promoter activity both in
vitro and in vivo, and SF-1 activates transcription from
the MIS promoter when transfected into heterologous
cell lines (Shen et al. 1994; Nachtigal et al. 1998). These
findings provide strong evidence that, in addition to its
function in gonadal formation, SF-1 is a key regulator
of MIS in vivo. The recent identification of a human SF-
1 heterozygote with a missense mutation that abolishes
sequence-specific DNA binding corroborates roles for
SF-1 in testis determination and in MIS regulation, since
this XY individual possesses streak gonads and retains
fully developed Mu¨llerian structures (Achermann et al.
1999).
Factors besides SF-1 are required to ensure tissue- and
sex-specific expression ofMIS. Like other genes in sexual
development, SF-1 functions in many tissues in addition
to the gonad, such as the adrenal gland and hypothal-
amus, whereas MIS expression is restricted to the fetal
testis and postnatal gonads. Furthermore, MIS tran-
scripts are detected just before SF-1 levels rise dra-
matically in males, suggesting that other factors initiate
MIS expression. Three additional transcription fac-
tors—Sox9, WT-1, and GATA-4—also regulate MIS-
gene expression, and, interestingly, these factors, like SF-
1, appear to act at early stages in the sex-determination
cascade or in the development of nongonadal tissues.
The first of these factors to be expressed in a testis-
specific fashion is Sox9, which binds to a more distal
site within the 180-bp proximal MIS promoter. This
HMG factor also interacts with SF-1 and cooperates in
the activation of a MIS reporter gene (De Santa Barbara
et al. 1998).
A second factor proposed to participate in the ex-
pression of MIS is the product of WT1. WT-1 is coex-
pressed with SF-1 during testis development and, like
SF-1, is required for gonad formation. Although WT-1
does not bind the MIS promoter sequence or activate
transcription by itself, it physically interacts with SF-1
and dramatically augmentsMIS expression in vitro. Syn-
ergy between SF-1 and WT-1 is abolished by mutations
in WT-1 that are found in patients with Wilms tumor
who have genital abnormalities (Nachtigal et al. 1998).
Increased dosage of DAX1, which causes XY sex-re-
versal in humans (Muscatelli et al. 1994; Zanaria et al.
1994), also abrogates WT-1 synergy with SF-1 on the
MIS promoter in vitro (Nachtigal et al. 1998). Finally,
the third gene implicated in MIS regulation encodes the
zinc-finger transcription factor GATA-4. GATA-4 pro-
tein is critical for development of heart and erythroid
cells and is also expressed in gonadal somatic cells. Dur-
ing development, GATA-4 is down-regulated in the em-
bryonic ovary, but it persists in the testis. Although it
activates the 180-bp MIS promoter in vitro (Viger et al.
1998), GATA-4 acquires its sexually dimorphic expres-
sion only late in gonadal development, at a stage, in
mice, when Mu¨llerian-duct regression is complete.
Hence it is unlikely to contribute to sex-specific expres-
sion of MIS, but it may participate in late embryonic
expression of MIS.
Accounting for the Tissue and Sex-Specific Expression
of MIS
Although embryonic expression of MIS is restricted
to the testis, none of the factors that control sexually
dimorphic expression of MIS are testis specific, in that
they are expressed in nongonadal tissues and also in the
fetal ovary. MIS expression may require the combined
activities of several factors—such as SF-1, Sox-9, and
WT-1—and thus may occur only in the gonad, where
all of these factors overlap, but this model cannot ex-
plain why MIS is silent in the fetal ovary, despite the
presence of low levels of SF-1, Sox9, and WT-1. Un-
known testis-specific factors may be required for MIS
expression in the embryonic testis, or, alternatively, un-
identified ovarian factors may repress expression of MIS
or may degrade MIS transcripts in the ovary. Precedence
for this suggestion comes from a recent study showing
that WNT4 inhibits androgen biosynthesis in the em-
bryonic ovary (see below and Vainio et al. 1999).
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SF-1: A Master Regulator of Male Sexual
Differentation
Activation and Suppression of Steroidogenesis in Fetal
Gonads
During differentiation of the internal genitalia, em-
bryonic Leydig cells express enzymes that are required
for the synthesis of sex steroids, enzymes such as 17a-
hydroxylase (P45017a/CYP17) and 3b-hydroxysteroid
dehydrogenase. By contrast, the fetal ovary does not
express these enzymes, illustrating the sexually dimor-
phic nature of steroid biosynthesis in the embryo (Ikeda
et al. 1994; Vainio et al. 1999; also see Davey et al. 1999
[in this issue]). As postulated for the adult adrenal and
gonads, the coordinate regulation of steroidogenesis in
fetal Leydig cells is most likely mediated by SF-1 (Parker
and Schimmer 1997). Although direct proof that SF-1
regulates hydroxylase expression in fetal Leydig cells is
hindered by the fact that Sf-1–null mice lack gonads, a
human patient with an inactivating SF-1 mutation pos-
sesses abnormal gonads and is phenotypically female,
suggesting that SF-1 controls fetal androgen biosynthesis
(Achermann et al. 1999).
Despite low levels of SF-1 in the fetal ovary, steroid-
ogenic enzymes are not expressed. Recent genetic studies
in mice show that steroidogenesis is actively suppressed
in the fetal ovary by a member of the Wnt gene family,
Wnt-4. In contrast to Sox9, Sox9, Gata-4, and Dmrt,
Wnt-4 appears to be down-regulated in the embryonic
testis. Female Wnt-4/ mice display masculinized inter-
nal genitalia; that is, they possess Wolffian-duct struc-
tures, owing to inappropriate testosterone biosynthesis
(Vainio et al. 1999). However, Wnt-4–null ovaries do
not express the Sertoli cell–specific genes MIS or DHH,
indicating that Wnt-4 is not a general repressor of testis
determination. Sertoli cell–gene expression may be re-
pressed in ovary by as-yet-unknown factors, or factors
required for the activation of these genes may simply be
absent in the ovary. Wnt-4–null mice provide the first
example of paracrine regulation of testicular hormone
expression. Future studies aimed at delineating both how
Wnt signaling suppresses steroidogenesis in the ovary
and whether other male-specific genes are repressed by
similar mechanisms will be of great interest.
InsL3, Testicular Descent, and SF-1
In addition to Mu¨llerian-duct regression and the onset
of steroidogenesis, a critical and late event in male sexual
development is the descent of the testes, through the
inguinal canals to the scrotum. Proper positioning of the
testes is determined by two genital ligaments, the cranial
suspensory ligament and the gubernaculum, or caudal
genital ligament. In males the gubernaculum grows, al-
lowing the testis to descend; by contrast, in females this
ligament fails to develop. Recently, reverse genetics has
identified Insl3 as a factor required for gubernaculum
development. In Insl3/ male mice, this ligament fails
to develop, resulting in bilateral cryptorchidism and ste-
rility (Zimmermann et al. 1999). InsL3 shows a male-
specific pattern of expression in the fetal testis, beginning
at E13.5 in mouse, and is not detected in the fetal ovary.
As with other hormones involved in male sexual differ-
entiation, there is good in vitro evidence that SF-1 reg-
ulates InsL3 (Zimmermann et al. 1998). Because the
timing and cell-specific expression of InsL3 differ from
those of MIS (Leydig cells vs. Sertoli cells), different SF-
1 cofactors and/or factors must interact with SF-1 on
the InsL3 and MIS promoters, to create distinct ex-
pression patterns.
Collectively, in vitro and in vivo data generated from
multiple investigations allow for tentative placement of
several autosomal genes in the mammalian sex-differ-
entiation pathway. Our current interpretation of existing
findings, which we have outlined in the text above, is
shown in figure 2. Clearly, a molecular understanding
of the latter stages of male sexual differentiation is much
more complete than that for initial events, which specify
testicular and ovarian development. Thus, efforts to
complete our understanding of this pathway will surely
be focused on determining how SRY directs testis de-
velopment and how or whether SRY links directly with
autosomal factors, such as SOX-9 and SF-1. Addition-
ally, the field anxiously awaits additional factors that,
by either repressing the male program (as shown for
Wnt-4) or actively promoting ovarian determination,
contribute to ovarian development (fig. 2).
Sex Determination, Gender, and Sexual Behavior
As our current knowledge of the mammalian sex-dif-
ferentiation pathway expands, a connection of this pro-
cess to the potential genetic regulation of sexual behavior
and sex-specific development of the brain is natural. At
least in invertebrate systems, a tangible genetic link has
been forged between the sex-development pathway and
normal courtship behavior. Two genes, fruitless and dis-
satisfaction, are now known to contribute to normal
male courtship behavior, by specifying the identity of
neurons required for execution of the reproductive be-
haviors. Additionally, these genes begin to define new
branches of the Drosophila sex-determination pathway
that are downstream of the transformer gene (tra) and
apparently independent of one another (Finley et al.
1998, and references therein). These findings offer an
interesting new perspective for those contemplating the
potential mechanisms governing sex differences in the
mammalian brain.
Previous studies have shown that steroids affect sex-
specific brain development during critical periods before
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Figure 2 Mammalian sex determination: a molecular view. Factors implicated in formation of the bipotential gonad and differentiation
of the ovary and testis are shown. Testis determination is initiated by SRY; however, molecular downstream targets of SRY and direct connections
of SRY with other regulatory factors are undetermined. During testis differentiation, Sox9, SF-1 and WT-1 regulate MIS. SF-1 also directs
expression of steroidogenic enzymes to produce testosterone and the Insl-3 factor, which is required for proper testis descent. Mutation of SRY,
SOX9, SF-1, or WT1 leads to 46,XY sex-reversed females. An additional dose of the DAX1 gene (or increased DAX1 protein) is postulated
to result in 46,XY sex reversal by direct antagonism of SF-1. By contrast, Wnt-4 blocks production of testosterone and therefore may block
segments of the male program in the ovary. The placement of DMRT1 in this pathway remains uncertain. Cross-regulation of SRY, SOX9, SF-
1, WT-1, and DAX1 may occur at multiple levels and is not depicted here.
and after birth, with consequences for adult behavior
(for review, see Breedlove 1992). For instance, perinatal
exposure of female animals to sex steroids can mascu-
linize adult behaviors, and androgens can alter the mor-
phology of brain nuclei, such as in the case of the sex-
ually dimorphic nucleus of the preoptic area of the
hypothalamus. Defining the precise contributions of in-
dividual nuclei to adult sexual behavior has been diffi-
cult. Moreover, the effects of sex steroids on brain de-
velopment are complex, because these steroids are
locally metabolized, as in the case of androgens. One
major metabolite of the aromatization of testosterone is
estrogen, which is generally assumed to be required in
male-specific brain development. The persistence of a
masculine preoptic area in androgen-insensitive rats sug-
gests that some developmental effects of testosterone oc-
cur after aromatization to estrogen (Breedlove 1992).
Interestingly, deficiency for the estrogen-receptor sub-
type ERa in mice disrupts male-specific aggressive and
mating behaviors but does not affect male sexual mo-
tivation (Ogawa et al. 1997). Moreover, male mice lack-
ing aromatase are fully capable of breeding (Fisher et al.
1998). These recent studies underscore how little is un-
derstood regarding the molecular basis of sex steroids
and their cognate nuclear receptors, in brain develop-
ment and sex differences in the brain.
Continued molecular and genetic investigations will
be required to identify which steroids and what nuclei
or brain regions are involved in sexually dimorphic brain
development. These studies promise to be challenging,
given the complexity of (a) steroid action on early brain
development and modulation of adult behavior and (b)
the indirect effects of steroid action on peripheral tissues.
It will be of great interest to know whether mammals
use a steroid-independent arm of the sex-determination
cascade to dictate sex differences in the brain, as Dro-
sophila does. During the next decade, the convergence
of vertebrate genetics, behavior analyses, and genomics
should elucidate the remaining mysteries of gonadal de-
velopment and may begin to provide a genetic rationale
for neurological and behavioral differences betweenmen
and women.
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